FY2025 EPS Estimates for Accuray Incorporated (NASDAQ:ARAY) Increased by Roth Capital

Accuray Incorporated (NASDAQ:ARAY) – Equities research analysts at Roth Capital lifted their FY2025 earnings per share estimates for Accuray in a research note issued to investors on Thursday, August 15th. Roth Capital analyst J. Wittes now forecasts that the medical equipment provider will post earnings of $0.02 per share for the year, up from their previous estimate of ($0.01). The consensus estimate for Accuray’s current full-year earnings is ($0.16) per share.

Accuray (NASDAQ:ARAY) last released its earnings results on Wednesday, August 14th. The medical equipment provider reported $0.03 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.03. The firm had revenue of $134.29 million during the quarter, compared to analyst estimates of $122.80 million. Accuray had a negative net margin of 4.99% and a negative return on equity of 44.46%. During the same period last year, the business earned ($0.03) earnings per share.

Accuray Trading Up 5.5 %

Accuray stock opened at $2.29 on Monday. The business’s fifty day moving average is $1.78 and its 200 day moving average is $2.08. Accuray has a one year low of $1.40 and a one year high of $3.10. The stock has a market capitalization of $227.27 million, a PE ratio of -10.41 and a beta of 1.45. The company has a debt-to-equity ratio of 4.05, a current ratio of 1.58 and a quick ratio of 0.78.

Insider Buying and Selling at Accuray

In other news, Director Joseph E. Whitters bought 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The stock was bought at an average price of $1.54 per share, with a total value of $77,000.00. Following the acquisition, the director now owns 511,053 shares of the company’s stock, valued at approximately $787,021.62. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 3.78% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ARAY. Armistice Capital LLC bought a new stake in Accuray during the second quarter worth approximately $910,000. Acuitas Investments LLC raised its holdings in Accuray by 14.7% during the 4th quarter. Acuitas Investments LLC now owns 708,553 shares of the medical equipment provider’s stock valued at $2,005,000 after buying an additional 91,053 shares during the period. Assenagon Asset Management S.A. purchased a new stake in Accuray during the 2nd quarter valued at $132,000. Williams & Novak LLC boosted its stake in Accuray by 259.2% during the second quarter. Williams & Novak LLC now owns 96,900 shares of the medical equipment provider’s stock worth $176,000 after buying an additional 69,925 shares during the period. Finally, Perritt Capital Management Inc boosted its stake in Accuray by 139.3% during the second quarter. Perritt Capital Management Inc now owns 120,000 shares of the medical equipment provider’s stock worth $218,000 after buying an additional 69,864 shares during the period. Institutional investors own 64.08% of the company’s stock.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.